These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10508045)

  • 21. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria.
    Roos JF; Lipman J; Kirkpatrick CMJ
    Intensive Care Med; 2007 May; 33(5):781-788. PubMed ID: 17342515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.
    Heil EL; Lowery AV; Thom KA; Nicolau DP
    Pharmacotherapy; 2015 Jan; 35(1):54-8. PubMed ID: 25556715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.
    Aitken SL; Altshuler J; Guervil DJ; Hirsch EB; Ostrosky-Zeichner LL; Ericsson CD; Tam VH
    Int J Antimicrob Agents; 2015 May; 45(5):541-4. PubMed ID: 25665726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic Dosing in Continuous Renal Replacement Therapy.
    Shaw AR; Mueller BA
    Adv Chronic Kidney Dis; 2017 Jul; 24(4):219-227. PubMed ID: 28778361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables.
    Georges B; Conil JM; Seguin T; Dieye E; Cougot P; Decun JF; Lavit M; Samii K; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2008 Apr; 46(4):157-64. PubMed ID: 18397688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8-Hour and 12-Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients.
    Kassel LE; Van Matre ET; Foster CJ; Fish DN; Mueller SW; Sherman DS; Wempe MF; MacLaren R; Neumann RT; Kiser TH
    Pharmacotherapy; 2018 Sep; 38(9):921-934. PubMed ID: 29906310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Jakob SM; Levkovich BJ; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Roberts JA; Shekar K; Fraser JF
    Int J Antimicrob Agents; 2021 Dec; 58(6):106466. PubMed ID: 34688834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
    Udy AA; Roberts JA; De Waele JJ; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2012 Jun; 39(6):455-7. PubMed ID: 22483562
    [No Abstract]   [Full Text] [Related]  

  • 34. A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU.
    Jonckheere S; De Neve N; De Beenhouwer H; Berth M; Vermeulen A; Van Bocxlaer J; Colin P
    J Antimicrob Chemother; 2016 Sep; 71(9):2538-46. PubMed ID: 27246236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment.
    Higuchi K; Ikawa K; Ikeda K; Ohge H; Sueda T; Houchi H; Morikawa N
    J Infect Chemother; 2008 Apr; 14(2):110-6. PubMed ID: 18622673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
    Tam VH; Louie A; Lomaestro BM; Drusano GL
    Pharmacotherapy; 2003 Mar; 23(3):291-5. PubMed ID: 12627925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime.
    Smith NL; Freebairn RC; Park MA; Wallis SC; Roberts JA; Lipman J
    Crit Care Resusc; 2012 Dec; 14(4):312-5. PubMed ID: 23230881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
    Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
    J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.